DMARGE MAGAZINE: Psychedelics Tycoon JJ Wilson On Psilocybin, MDMA & Australia’s Mental Health Renaissance
Click on Image to Read Full Interview.
We hope you find what you’re looking for. You can email us if you need additional help.
Click on Image to Read Full Interview.
The announcement follows a national reclassification of MDMA and psilocybin for therapeutic uses in Australia as a result of the years-long effort of Mind Medicine Australia and its dedicated supporters Highlights: • Signed Purchase Orders with Mind Medicine Australia to
Highlights: • $1.85 million in proceeds received through a strategic offering of units at $0.325 per unit with each unit comprised of one common share and one-half of one (1/2) Common Share purchase warrant exercisable at $0.50, for total potential
Regulator Filings
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th